EU drugs agency publication on hepatitis C and injecting drug use looks at impact, costs and policy options

Publié le 1 Janvier 2005
Mis à jour le 10 septembre 2019

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the EU drugs agency, has recently published its latest scientific monograph, Hepatitis C and injecting drug use: impact, costs and policy options. This publication brings together research by international experts from the hepatitis C, drug use and public health fields. It combines analyses on the impact and costs of hepatitis C virus (HCV) infection among injecting drug users (IDUs) so as to inform future policy making in the European Union.

Auteur : Hope V, Ncube F
Eurosurveillance. European communicable disease quarterly, 2005, vol. 10, n°. 1-3, p. p.67